簡體
|
繁體
HOME
CORPORATE INFO
CORPORATE INFO
Introduction
Chairman's Statement
Corporate Structure
Board of Directors
TECHNOLOGY
TECHNOLOGY
R&D Capability
bFGF
BFS
PRODUCTS
PRODUCTS
bFGF Series
Beifushu Eye Drops
Beifushu Gel
Beifuji Spray
Beifuji Lyophilized Powder
Beifuxin Gel
Ophthalmic Products from Third Parties
Lodized Lecithin Capsules
Xalatan Latanoprost Eye Drops
Xalacom Latanoprost and Timolol Maleata Eye Drops
Surgical Products from Third Parties
Carisolv Caries minimally invasive remove rotten Gel and excavation Tool
Yi Xue An Granules
Eye Health Care Products
Beifu? shuhui capsules
INVESTOR RELATIONS
INVESTOR RELATIONS
Announcement
Financial Report
Circulars
Monthly Return
Constitutional Documents
Next Day Disclosure Returns
Others
NEWS CORNER
NEWS CORNER
Company News
Investee News
Industrial News
FEEDBACK
CONTACT US
Company News
Investee News
Industrial News
Company News
Year:
All Years
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2019
12/12/2019
Essex Bio-Technology and Mitotech Announce First Patient First Visit in U.S. FDA Second Phase 3 Clinical Trial of SkQ1
21/08/2019
Essex Bio-Admission of Product to the PRC National Drug List for Reimbursement Beifuxin Newly Listed and the Other Three Products Remain on the List
13/08/2019
Profit-After-Tax Up 31% to HK$ 129 million, Net Gain of HK$ 18 million from Partial Divestment of MeiraGTx Recorded in Other Comprehensive Income
02/08/2019
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
19/07/2019
Essex Bio-Technology and Mitotech AnnounceTopline Results from VISTA-1,Phase 3 Clinical Trial in U.S. FDA of a First-In-Class Drug for Dry Eye Disease
15/05/2019
Essex Bio-Technology Included by MSCI as A Constituent of The MSCI China Small Cap Index
29/04/2019
Essex Bio-Technology Announces Upcoming Joint Presentation with Mitotech and Ora at ARVO 2019 Annual Meeting
12/03/2019
FY18 Turnover & Net Profit grew 30.8% and 38.1% to HK$1,176.5 million & HK$ 231.1 million, respectively
11/01/2019
The cellular growth factor project of Essex Bio-Technology Limited was honored with the second prize of National Scientific and Technology Progress Award
2018
30/10/2018
Essex Bio-technology Entered into Convertible Notes Purchase Agreement and License Agreement with DB Therapeutics—Its Radioactive Bandages For The Treatment Of Non-Melanoma Skin Cancer (NMSC)
29/10/2018
Essex Bio-Technology Announces First Patient First Visit in U.S. FDA Phase 3 Clinical Trial of SkQ1 Occurred on 27 October 2018
22/08/2018
Preservative-free Single-dose Sodium Hyaluronate Eye Drops Obtained Approval from SDA for Commercilisation in China
10/08/2018
Group Turnover and Profit in the First Half of 2018 Increased 28.3%
24/07/2018
Essex Bio-Technology Investing in Chengdu Shanggong Medical Technology Co.,Ltd
18/07/2018
Essex Bio-Technology Enters into Global Co-Development Agreement with Mitotech
13/04/2018
Zhuhai Essex Bio-Pharmaceutical Obtained a GMP Cerficate for Preservative-Free Single-Dose Tobramycin Eye Drops
10/04/2018
Essex Bio-Technology appoints Dr.Xue Qi as Chief Scientific Officer for its R&D centre in USA
19/03/2018
Group Profit Recorded Growth of 22.8% in 2017
06/03/2018
Change of Company Logo Represents a Transformation for Essex Bio-Technology
26/02/2018
Essex Bio-Technology announces investment in MeiraGTx, a biotech company developing novel gene therapy treatments
2017
22/05/2017
AC Immune and Essex Bio-Technology announce research collaboration for neurodegenerative diseases and neuroinflammation
2016
07/04/2016
HUMACYTE,INC.,one of the investments of the group,made research and development progress in Q1 2016
21/03/2016
Group turnover and profit recorded growth of 26.2% to HK$654M & 39.4% to HK$104.9 respectively
2015
28/08/2015
EssexBio and Tasly to co-develop recombinant protein drugs under Strategic Co-Operation Framework Agreement
18/03/2015
Group turnover and profit recorded growth of 49.3% & 37.1% respectively
2014
07/08/2014
Growth of 40.1% & 13.8% in turnover and profit respectively
15/05/2014
Announcement obtaining of a health food certificate by a wholly-owned subsidiary
28/04/2014
Zhuhai Essex Bio-Pharmaceutical Company Limited Bestowed the Award of Outstanding Enterprise of 2013(Guangdong Province)
17/02/2014
Announcement import and service agreement with Pfizer international trading (ShangHai) LTD.
2013
31/12/2013
Obtaining of a certificate of good manufacturing practices for human drugs by a wholly-owed subsidiary
2011
03/08/2011
Group recorded first half growth of 53.6% & 34.4% in turnover and profit respectively
23/06/2011
Essex Bio-Technology Limited successfully transferred the listing from the gem board to the main board (stock code on main board: 1061) (stock code on gem: 8151)
12/05/2011
Group pharmaceutical business recorded first quarter growth of 74.3% & 44.0% in turnover and profit respectively
28/03/2011
Group pharmaceutical business recorded growth of 25.4% & 58.7% in turnover and profit respectively
2010
04/11/2010
Group pharmaceutical business recorded growth of 22.4% & 45.1% in turnover and profit respectively
11/08/2010
Group pharmaceutical business recorded growth of 22.6% & 38.3% in turnover and profit respectively
25/03/2010
Group pharmaceutical business recorded moderate growth of 25.6% in revenue
Guangdong Top Five Manufacturing Enterprises
High-Tech Product-Beifushu Gel
2nd Prize for National S&T Progress Award
High and New Tech Enterprises Certificate
GMP Certificate
Good Quality Control Practice Certificate
High-Tech Product- Beifushu Eye Drops
High-Tech Product-Beifuji Spray
High-Tech Product-Beifuji Lyophilized Powder
High-Tech Product- Beifuxin Gel
The Award of Outstanding Enterprise of 2013
网上购买彩票
快乐12开奖结果第17期
时时彩龙虎合是骗局么
做借贷赚钱吗
2018最新捕鱼送分平台
江西丫丫奉新麻将癞子
二分时时彩全天人工
幸运农场现场开奖
快乐12开奖结果走势图
彩金捕鱼旧版本
剑三什么专精比较赚钱
华东15选5精准预测
11选5稳赚任选3计划
股票配资顶牛
排列五开奖近50期
年后赚钱
玩车教授怎么赚钱